Entry and replication of positive-sense, RNA viruses

丙型肝炎病毒是一个重大的全球公共卫生问题，全世界约有7000万人感染。目前还没有批准的疫苗来对抗HCV感染，据估计，仅在美国每年就有4万多例新感染，而在世界其他地区每年有300万至400万例新感染（疾病控制中心）。许多常见病毒基因型的慢性丙型肝炎病毒感染可以通过一种有效但昂贵的抗病毒治疗（每名治疗患者7万美元）治愈。然而，药物治疗并不是在世界范围内根除丙型肝炎病毒感染的可行途径，因为这样做的费用过高。此外，成功治疗感染一种病毒基因型的患者并不排除再次感染另一种病毒基因型。药物治疗方法也因大多数受影响的个人不知道自己被感染而变得复杂，许多人从事危险行为，例如静脉注射药物。简而言之，最好的长期解决办法是投入大量智力和财力资源，发现和开发一种多价疫苗，有效对抗大多数（如果不是全部的话）丙型肝炎病毒基因型。

HCV represents a major global public health problem, infecting approximately 70 million people worldwide. There is currently no approved vaccine to counter HCV infection, and it is estimated that there are more than 40,000 new infections annually in the US alone with an additional 3-4 million new infections per year in the rest of world (Center for Disease Control). Chronic HCV infection with many of the common viral genotypes is curable by an effective, albeit expensive, antiviral therapy ($70,000/treated patient). Drug treatment is not, however, a feasible route to worldwide eradication of HCV infection, as the cost of doing so would prohibitive. Moreover, successful treatment of a patient infected with one viral genotype does not preclude re-infection with another. The drug treatment approach is also complicated by the fact that most affected individuals are unaware that they are infected, and many engage in risky behaviors, such as intravenous drug use. Simply put, the best long term solution is to invest considerable intellectual and financial resources in discovery and development of a polyvalent vaccine effective against most, if not all, HCV viral genotypes. HCV is an enveloped virus with two surface glycoproteins, E1 and E2, which are critical for entry and immune escape. Since becoming an independent researcher, my laboratory has developed a cost-, labor- and time-efficient method for large-scale production of recombinant glycoproteins in mammalian cell lines with native, post-translational modifications, enabling determination of the core domain of HCV E2 structure in complex with an Fab fragment. This structure revealed that HCV E2 does not share any similarity to other viral glycoproteins, including those from closely related viruses, suggesting that HCV uses a novel entry mechanism.